Macrogenics (MGNX) Misses Q1 EPS by 29c, Revenues Miss

Macrogenics (NASDAQ: MGNX) reported Q1 EPS of ($0.90), $0.29 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $16.88 million versus the consensus estimate of $27.95 million.

“With the recent launch and commercialization of MARGENZA, we are delivering on our vision to provide potentially life-changing therapeutics to patients with cancer. We are well positioned to advance this mission as the growing body of data emerges from our deep pipeline of clinical and pre-clinical product candidates," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, “and we look forward to sharing additional data with you as the year progresses.”

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• West Fraser Timber Co. Ltd. (WFG) Tops Q1 EPS by 17c
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance